Home › Compound Library › Fluvoxamine (Luvox)

Fluvoxamine (Luvox)

SSRIprescriptionoral · inferred

SSRI with uniquely potent sigma-1 receptor agonism, the only SSRI with clinically relevant sigma activity. First-line for OCD (FDA-approved). Strong CYP1A2 and moderate CYP2C19 inhibitor; significant drug interactions (contraindicated with tizanidine, theophylline). No active metabolites. Nonlinear pharmacokinetics at higher doses. Also studied for COVID-19 outcomes (sigma-1 mediated anti-inflammatory effect via IRE1/XBP1s pathway).

Projected serum levels — 50 mg, twice daily

Fluvoxamine (Luvox)
Fluvoxamine (Luvox) modeled serum levels, 50 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 0.63 1.3 1.9 2.5 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Fluvoxamine (Luvox) modeled serum levels with a loading dose of 121 mg, then 50 mg twice daily The first dose is larger so levels approach steady state faster. 0 0.63 1.3 1.9 2.5 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 50 mg twice daily (oral).

Loading schedule: 121 mg on day 1, then 50 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 2.4 mg, trough ≈ 1.6 mg body load. Population-based estimate over 15 days for a 50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
SSRI
Route modeled
Oral
Model confidence
inferred
Half-life
15 h
Common dose
50 mg
Suggested maximum
300 mg/day
Reference dose range
25–300 mg (single dose)
Suggested cadence
twice daily
Validated against
100 mg oral — Cmax 0.040 mg/L at 3 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Fluvoxamine (Luvox) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Fluvoxamine (Luvox) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Fluvoxamine (Luvox) Serotonin risk

    25I-NBOMe and Fluvoxamine (Luvox) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Fluvoxamine (Luvox) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Fluvoxamine (Luvox) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Fluvoxamine (Luvox) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Fluvoxamine (Luvox) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Fluvoxamine (Luvox) Serotonin risk

    4-AcO-DMT (Psilacetin) and Fluvoxamine (Luvox) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + Fluvoxamine (Luvox) Serotonin risk

    5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and Fluvoxamine (Luvox) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 440 modeled interaction pairings for fluvoxamine (luvox) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19 (TOGETHER trial) Reis G et al. · Lancet Global Health, 2022 DOI

    Large RCT (1497 patients) finding fluvoxamine 100 mg BID reduced COVID-19 hospitalization/ED visits by 32% versus placebo, attributed to sigma-1 receptor-mediated anti-inflammatory effects.

  2. Fluvoxamine for the treatment of obsessive-compulsive disorder: a meta-analysis Fibbe LA et al. · European Neuropsychopharmacology, 2012 DOI

    Meta-analysis confirming fluvoxamine's efficacy for OCD with Y-BOCS reduction comparable to other SSRIs, establishing it as a first-line treatment option for obsessive-compulsive disorder.

2 published studies referenced in the app, each with a plain-language summary.